Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide
Hangzhou Sciwind Biosciences presented data at the 86th American Diabetes Association Scientific Sessions showing its cAMP-biased GLP-1 receptor agonist, ecnoglutide, achieved a 35% greater weight loss than semaglutide in a head-to-head study involving 163 obese adults. The trial, conducted across 17 Chinese research centers, also demonstrated a 20% greater reduction in waist circumference and nearly double the rate of patients achieving ≥10% weight loss by week 20, with improved metabolic safety compared to traditional GLP-1 agonists.
Hangzhou Sciwind Biosciences announced interim results from the SLIMMER-UP-SWITCH study, comparing its cAMP-biased GLP-1 receptor agonist ecnoglutide to semaglutide in 163 obese adults (BMI ≥30 kg/m²) across 17 research centers in China. At week 20, ecnoglutide delivered a 35% greater mean weight loss (-12.8% vs. -9.5% for semaglutide) and a 20% greater reduction in waist circumference (10.5 cm vs. 8.7 cm), with nearly twice as many patients achieving ≥10% weight loss. The study, presented as a Late-Breaking abstract at the 86th American Diabetes Association Scientific Sessions, highlights ecnoglutide’s mechanism—optimizing GLP-1 receptor signal transduction to balance efficacy and tolerability. Unlike traditional GLP-1 agonists, which fully activate weight loss pathways but also trigger gastrointestinal side effects, ecnoglutide’s cAMP-biased approach reduces central obesity while maintaining a favorable safety profile. Professor Linong Ji, Director of Endocrinology at Peking University People’s Hospital, emphasized ecnoglutide’s potential to lower risks of type 2 diabetes and metabolic syndrome by targeting abdominal fat accumulation. The drug’s design, rooted in Nobel Prize-winning research, addresses long-standing challenges in weight management therapies. Participants were randomized 1:1 to receive once-weekly subcutaneous injections of either ecnoglutide or semaglutide at a 2.4 mg maintenance dose. Results confirmed ecnoglutide’s superior weight loss without compromising gastrointestinal safety, aligning with prior SLIMMER study findings. Dr. Hai Pan, Sciwind Biosciences’ CEO, called the breakthrough ‘a major step forward’ in metabolic disease treatment, underscoring the importance of precise biological regulation over incremental target stacking. The study provides direct clinical evidence supporting ecnoglutide’s role as the first approved cAMP-biased GLP-1 receptor agonist.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.